DANCANN Aktie

 

COPENHAGEN, Denmark, 9 July 2025 – DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby provides additional information regarding the bridge loan facility previously announced (the “Loan”). Terms of the Loan The Company has entered into a bridge loan agreement in the amount of DKK 2 million with a syndicate of ten (10) investors (collectively, the “Lenders”), including JEQ Capital AB, the Company's largest current shareholder. None of the Lenders are considered related parties to the Company under applicable regulations, and...

COPENHAGEN, Denmark, 9 July 2025 – DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby announces that the Company has received a conditional sales agreement regarding the sale of its production facility, Biotech Pharm1 (“BP1”), at a total consideration of EUR 1.25 million (DKK 9.32 million). In continuation of this, the Company has secured bridge financing for DKK 2 million to bridge liquidity until final sale of BP1, and to help propel its new Maturity2028 strategy. Conditional sales agreement for BP1 Since the Company's...

København, Danmark, 23. maj 2025 – DanCann Pharma A/S (Spotlight: DANCAN) (“DanCann Pharma” eller “Selskabet”), et dansk biofarmaceutisk selskab med fokus på cannabinoider, meddeler hermed, at Selskabet har offentliggjort sin rapport for første kvartal (Q1) 2025. Rapporten er vedhæftet denne meddelelse og er tilgængelig på Selskabets hjemmeside: www.dancann.com. Hovedtal for Selskabet – 1. kvartal 2025 (i DKK 1.000)   +---------------+-------------------+-------------------+---------+---------+ |Periode |01.01.25 – 31.03.25|01.01.24 – 31.03.24|Hele 2024|Hele 2023| +------------...

COPENHAGEN, Denmark, 23 May 2025 – DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby announce that the Company has published its report for the first quarter (Q1) of 2025. The Q1-2025 report is available as an attached document to this press release and at www.dancann.com. Summary: Group Key Figures Q1-2025   +-------------+----------+-------------------+----------------+----------------+ |DKK 1,000 |01/01/25 |01/01/24 – 31/03/24|2024 (Full year)|2023 (Full year)| | |– 31/03/25| |...

COPENHAGEN, Denmark, 19 May 2025 – DanCann Pharma A/S (SS: DANCAN) (“DanCann Pharma” or the “Company”), a Danish company powered by cannabinoids, hereby announces that the Company has obtained approval from the Danish Medicines Agency for the distribution of Bedrolite® and Bedrobinol® under the Danish Pilot Programme for medicinal cannabis, through its wholly owned subsidiary CannGros ApS. The approval of these new products is in line with the Company's communicated guidance and is expected to have a positive impact on sales performance going forward. DanCann Pharma has received confirmation...

COPENHAGEN, Denmark, 25 April 2025 – DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby announces the recent adoption of Bill L135 by the Danish Parliament, which establishes a permanent legislative framework for the current medicinal cannabis Pilot Programme and formalizes the regulatory environment for medical use of cannabis in Denmark. This legislative milestone confirms Denmark's commitment to a long-term, structured integration of cannabinoid-based medicines into the national healthcare system. Bill L135 was adopted...

COPENHAGEN, Denmark, 24 April 2025 – DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby announces an update to its financial calendar for the remainder of the fiscal year 2025. The updated financial calendar is also available on the Company's website at www.dancann.com. Updated Financial Calendar for 2025:   Annual Report 2024: April 04, 2025 (PM 06:00 CET)   Annual General Meeting: April 24, 2025 (AM 09:00 CET)   Q1 2025 Report: May 23, 2025 (PM 06:00 CET)   Q2 2025 Report: August 25, 2025 (PM 06:00...

held in DanCann Pharma A/S, CVR-no. 39 42 60 05 (“Company”) Thursday, 24 April 2025 at 09:00 am (CET) On 24 April 2025 at 09:00 am (CET), the annual general meeting of 2025 was held in the Company at the Company's address, Rugvænget 5, 6823 Ansager, Denmark. The agenda for the annual general meeting was as follows: `. 1. 1. 1. 1. 1. 1. The chairman's report on the activities of the Company in the past financial year 2. Adoption of the annual report for 2024 3. Covering of loss pursuant to the adopted...

The Board of Directors hereby convenes the annual general meeting 2025 of DanCann Pharma A/S, CVR-no. 39 42 60 05 (“Company”), to be held on Thursday, 24 April 2025 at 09:00 am (CET) at DanCann Pharma A/S' address, Rugvænget 5, 6823 Ansager, Denmark The agenda for the annual general meeting is as follows: The chairman's report on the activities of the Company in the past 1. financial year   Adoption of the annual report for 2024 2.   Covering of loss pursuant to the adopted annual report for 2024 3.   Election of members of the Board of Directors...

APRIL 2025 Copenhagen, Denmark, April 4, 2025 — DanCann Pharma A/S (SS: DANCAN) (“DanCann Pharma” or the “Company”), a leading Danish biopharmaceutical company specialized in cannabinoid-based therapies, hereby announces that the Board of Directors and the Chief Executive Officer have today approved and published the Annual Report for the financial year 2024. The report is now available on the Company's website and via this press release. Financial Highlights for 2024: · Revenue amounted to DKK 7.37 million, reflecting a year-over-year increase of 21.4% (2023: DKK 6.07 million)....

COPENHAGEN, Denmark, 27 March 2025 DanCann Pharma A/S' annual report 2024 was planned to be released on 31 March 2025, and the annual general meeting 2025 was planned to be held on 14 April 2025. The release of the annual report 2024, the notice of the annual general meeting 2025 and the holding of the annual general meeting 2025 are postponed to the following dates: Release of annual report 2024 4 April 2025 Notice of annual general meeting 2025 4 April 2025 Annual general meeting 2025 24 April 2025 DanCann Pharma A/S' financial calendar has been updated...

Das Instrument DAN0 DK0063631999 DANCANN PHARMA DK 1 EQUITY hat seinen ersten Handelstag am 24.02.2025: CONTINUOUS AUCTION SPECIALIST, PAG PAG_EQU, SettlCurr EUR, CCP Y The instrument DAN0 DK0063631999 DANCANN PHARMA DK 1 EQUITY has its first trading date on 24.02.2025: CONTINUOUS AUCTION SPECIALIST, PAG PAG_EQU, SettlCurr EUR, CCP Y...

Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: Anmerkungen DK0061410487 DanCann Pharma A/S 21.02.2025 DK0063631999 DanCann Pharma A/S 24.02.2025 Tausch 1000:1 CA85941M1041 Sterling Metals Corp. 21.02.2025 CA85941M8806 Sterling Metals Corp. 24.02.2025 Tausch 10:1 CA02527W1095 American Copper Development Corp. 21.02.2025 CA02527W2085 American Copper Development Corp. 24.02.2025 Tausch 5:1 KYG7552D1354 Younited Financial 21.02.2025 LU2999653251 Younited Financial 24.02.2025 Tausch 1:1...